Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724788 | 0.91 | PIK3CA (0.55) | RIPK1PIK3CAUSP30GPR119 | |
| SCHEMBL2727759 | 0.91 | RIPK1 (0.47) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL31538706 | 0.91 | ESR2 (0.50) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL3755366 | 0.86 | RIPK1 (0.47) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL10456601 | 0.85 | NR1H2 (0.45) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL2994022 | 0.85 | RIPK1 (0.43) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL10455582 | 0.85 | NR1H2 (0.45) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL19657617 | 0.85 | RIPK1 (0.64) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL6126393 | 0.85 | MEN1 (0.48) | RIPK1ESR2NR1H2PIK3CAUSP30 | |
| SCHEMBL13765601 | 0.84 | RIPK1 (0.48) | RIPK1ESR2NR1H2PIK3CAUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | EXELIXIS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305093-A1 | Inhibitors of mTOR and Methods of Making and Using | MTOR, RICTOR, RPTOR | RIPK1 1682/4885ESR2 4140/4885NR1H2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.